Domo Deploys Poison Pill to Shield $400M in NOLs During Strategic Sale

summarizeSummary

Domo implemented a poison pill with a 4.9% ownership cap to protect its net operating losses, a key asset as it sells its core business to Progress Software for $400 million.

check_boxKey Events · Corporate Governance and Compliance · DOMO

• Poison Pill Adopted

  The board adopted a Tax Benefits Preservation Plan with a 4.9% trigger threshold, designed to prevent an ownership change that would limit the use of NOLs.

• NOL Protection Rationale

  Valuable NOLs and other tax attributes are safeguarded by the plan, as they could be substantially limited if a 5% shareholder increases ownership by more than 50 percentage points over three years.

• Rights Dividend Declared

  One preferred stock purchase right was distributed per share of Class A and Class B common stock, exercisable at $17.50 per right—far above the current $3.85 stock price.

• Expiration and Redemption

  The rights expire on July 20, 2029, unless redeemed earlier by the board at $0.001 per right or upon a board-approved merger.

auto_awesomeAnalysis · DOMO · Technology

To protect its net operating losses—a critical asset given the company's going-concern warning and the pending $400 million sale of its core business to Progress Software—Domo adopted a shareholder rights plan with a 4.9% trigger. The pill blocks any investor from accumulating more than 4.9% of the stock without board approval, which would otherwise trigger an ownership change under Section 382 and severely curtail the use of the NOLs. This defensive move preserves the value of the tax attributes for the post-sale entity, which will retain the public listing. With an exercise price of $17.50 per right, far above the current $3.85 stock price, the pill acts as a deterrent rather than an immediate dilution threat. The plan expires in July 2029 and can be redeemed by the board at $0.001 per right before a triggering event.